The Economics of Malaria Vaccine Development.
Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).
Vaccine and Infectious Diseases Unit, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia; Division of Therapeutics, Monash Institute of Medical Engineering (MIME), Monash University, Melbourne, Victoria, Australia. Electronic address: magdalena.plebanski@monash.edu.
Magdalena
M
Plebanski
Vaccine and Infectious Diseases Unit, Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia; School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Katie L
KL
Flanagan
D002986:Clinical Trials as Topic; D006801:Humans; D064789:Immunity, Heterologous; D008288:Malaria / Q000191:economics* / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000191:economics* / Q000592:standards*; D012737:Sex Factors
D017780:Malaria Vaccines